Biomarker testing in genitourinary (GU) pathology is evolving, facing challenges such as diagnostic standardization, direct marketing to oncologists, and unnecessary test repetitions. In this roundtable discussion, four GU pathologists emphasize the importance of their role in overseeing molecular testing and integrating results into patient care. Next-generation sequencing (NGS) has markedly changed treatment landscapes for cancers like prostate and bladder, offering more precise prognostic stratifications. However, the need for effective coordination between oncologists and pathologists is critical for optimizing patient outcomes.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
